Dr. Rule on the MabCute Study in Indolent Non-Hodgkin Lymphoma
June 14th 2019Simon Rule, MD, PhD, Plymouth University Medical School, discusses results of the phase III MabCute study evaluating subcutaneous rituximab as maintenance after standard subcutaneous rituximab induction and maintenance in patients who have relapsed or refractory indolent non-Hodgkin lymphoma.
Read More